Type 2 Diabetes - Pipeline Review, H2 2015

Type 2 Diabetes - Pipeline Review, H2 2015

Code: GMDHC6943IDB | Published: Dec-2015 | Pages: 1335 | Global Markets Direct
Price :

* Required Fields



Type 2 Diabetes - Pipeline Review, H2 2015


Global Markets Directs, Type 2 Diabetes - Pipeline Review, H2 2015, provides an overview of the Type 2 Diabetess therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Type 2 Diabetes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 2 Diabetes and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Type 2 Diabetes
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Type 2 Diabetes and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Type 2 Diabetes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Type 2 Diabetes pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Type 2 Diabetes
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Type 2 Diabetes pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
3SBio Inc.
Addex Therapeutics Ltd
Advinus Therapeutics Ltd.
Aegis Therapeutics, LLC
Alchemia Limited
Alize Pharma SAS
AlphaMab Co., Ltd
Amarantus Bioscience Holdings, Inc.
Ambrx, Inc.
Amgen Inc.
Anchor Therapeutics, Inc.
AntriaBio, Inc.
Aphios Corporation
Araim Pharmaceuticals Inc.
Arisaph Pharmaceuticals, Inc.
ArisGen SA
Array BioPharma Inc.
Arrien Pharmaceuticals, LLC
Artery Therapeutics, Inc.
Astellas Pharma Inc.
AstraZeneca Plc
AUS Bio Limited
Avaxia Biologics, Inc.
Bayer AG
Beta-Cell NV
Betagenon AB
Biocon Limited
Biodel Inc.
Biogenomics Limited
BioLingus AG
BioRestorative Therapies, Inc.
BioTherapeutics Inc.
BioTime, Inc.
Boehringer Ingelheim GmbH
Boston Therapeutics, Inc.
Braasch Biotech LLC
Bristol-Myers Squibb Company
C4X Discovery Limited
Caldan Therapeutics Limited
Cardax Pharmaceuticals, Inc.
Cardiolynx AG
Carlina Technologies SAS
Carmot Therapeutics, Inc.
Catabasis Pharmaceuticals, Inc.
Celon Pharma Sp. z o.o.
ChemoCentryx, Inc.
Chipscreen Biosciences Ltd
Chong Kun Dang Pharmaceutical Corp.
CJ HealthCare Corp.
CohBar, Inc.
Connexios Life Sciences Pvt. Ltd.
CSL Limited
CureDM, Inc.
CymaBay Therapeutics, Inc.
Daewoong Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
Dance Biopharm Inc.
Debiopharm International S.A.
Delpor, Inc.
Diabetica Limited
Diabetology (Products) Ltd
DiaMedica Inc.
Diasome Pharmaceuticals, Inc.
DiscoveryBiomed, Inc.
Dong-A Socio Group
Eisai Co., Ltd.
Elcelyx Therapeutics, Inc.
Eli Lilly and Company
enGene, Inc
Enzo Biochem, Inc.
Epichem Pty Ltd
Esperion Therapeutics, Inc.
Euroscreen S.A.
Evotec AG
F. Hoffmann-La Roche Ltd.
FibroStatin SL
Flamel Technologies S.A.
Foresee Pharmaceuticals, LLC
Generex Biotechnology Corporation
Genfit SA
Genovate Biotechnology Co., LTD.
GlaxoSmithKline Plc
Glide Pharmaceutical Technologies Limited
Glucox Biotech AB
Gubra ApS
GW Pharmaceuticals Plc
Hadasit Medical Research Services & Development Lt
Halozyme Therapeutics, Inc.
HanAll Biopharma Co., Ltd.
Handok Inc.
Hanmi Pharmaceuticals, Co. Ltd.
Heptares Therapeutics Limited
Hua Medicine Ltd.
Hyundai Pharmaceutical Co., Ltd.
Innopharmax Inc.
Insusense Therapeutics ApS
Intarcia Therapeutics, Inc.
Integral Molecular, Inc.
IntelliCell BioSciences Inc.
Intercept Pharmaceuticals, Inc.
Intrexon Corporation
Ionis Pharmaceuticals, Inc.
IPCA Laboratories Limited
Islet Sciences, Inc.
iTherX, Inc.
Japan Tobacco Inc.
Jeil Pharmaceutical Co., Ltd.
Jenrin Discovery, Inc.
Jiangsu Hengrui Medicine Co., Ltd.
Johnson & Johnson
Kadimastem Ltd.
Kadmon Corporation, LLC
Kainos Medicine, Inc.
Kareus Therapeutics, SA
Kissei Pharmaceutical Co., Ltd.
Lexicon Pharmaceuticals, Inc.
LG Life Science LTD.
Ligand Pharmaceuticals, Inc.
Lonestar Heart, Inc.
Longevity Biotech, Inc
Magnus Life Science
Medesis Pharma S.A.
Medestea Research & Production S.p.A.
MedImmune, LLC
Mellitech SAS
Merck & Co., Inc.
Mesoblast Limited
Metabolic Solutions Development Company, LLC
Metabolys S.A.S.
MI.TO. Technology S.r.L.
MicroBiome Therapeutics LLC
MidaSol Therapeutics LP
Mitsubishi Tanabe Pharma Corporation
Naia Limited
NatureWise Biotech & Medicals Corporation
NeoPharm Co., Ltd.
Neurimmune Holding AG
Neurocrine Biosciences, Inc.
NGM Biopharmaceuticals, Inc.
Nimbus Therapeutics, LLC
NOD Pharmaceuticals, Inc.
Nordic Bioscience A/S
Novartis AG
Novo Nordisk A/S
Noxxon Pharma AG
Omeros Corporation
OPKO Health, Inc.
Oramed Pharmaceuticals, Inc.
Orbis Biosciences, Inc.
Orchid Chemicals & Pharmaceuticals Ltd
Orgenesis, Inc.
Panacea Biotec Limited
Paras Biopharmaceuticals Finland Oy
Peptron, Inc.
Pfizer Inc.
PharmaIN Corporation
Pharnext SAS
PhaseBio Pharmaceuticals, Inc.
Poxel SA
Progen Pharmaceuticals Limited
Prometheon Pharma, LLC
ProMetic Life Sciences Inc.
ProteoTech, Inc.
Prothena Corporation Plc
Purzer Pharmaceutical Co., Ltd.
Quantum Pharmaceuticals
Reata Pharmaceuticals, Inc.
Receptos, Inc.
Red Glead Discovery AB
Regeneron Pharmaceuticals, Inc.
Rhizen Pharmaceuticals S.A.
Rhythm Pharmaceuticals, Inc.
Saniona AB
Sanwa Kagaku Kenkyusho Co., Ltd.
SATT Conectus Alsace SAS
SBI Pharmaceuticals Co., Ltd.
Seres Therapeutics, Inc.
Serodus ASA
Serometrix, LLC
Sevion Therapeutics, Inc.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Shanghai Pharmaceutical Co., Ltd.
Shantani Proteome Analytics Pvt. Ltd.
Shionogi & Co., Ltd.
Sihuan Pharmaceutical Holdings Group Ltd.
Sirona Biochem Corp
SJT Molecular Research, S.L.
SK Chemicals Co., Ltd.
Sprint Bioscience AB
Starpharma Holdings Limited
Stelic Institute & Co.
Strongbridge Biopharma plc
Sumitomo Dainippon Pharma Co., Ltd.
Summit Therapeutics Plc
Taisho Pharmaceutical Holdings Co., Ltd.

Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]

2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal

3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.


There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare
Global Markets Direct

Our Clients